



As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.

Learn more: [PMC Disclaimer](#) | [PMC Copyright Notice](#)

J Clin Aesthet Dermatol. 2014 Nov; 7(11): 16–24.

PMCID: PMC4255694 | PMID: [25489378](#)

[Andrew F. Alexis](#), MD, MPH and [Paul Blackcloud](#), BA


Seemal R. Desai, MD, FAAD, Section Editor and Andrew Alexis, MD, FAAD, Section Editor

► [Author information](#) ► [Copyright and License information](#) [PMC Disclaimer](#)

| ESTIMATED PREVALENCE                            | STUDY DESIGN | REFERENCE |
|---|--------------|-----------|
| 1.9% in African Americans 3.6% in Caucasians    |              | —         |
| 1.3% in African Americans 2.5% in Caucasians    |              | —         |
| 0.06% in African Americans 0.225% in Caucasians |              | —         |
| 0.22% in African Americans 1.28% in Caucasians  |              | —         |
| 0% in Indians of Latin America                  |              | —         |
| 0.19% in Egypt                                  |              | —         |
| 2.6% in Kenya                                   |              | —         |
| 2.8% in Uganda                                  |              | —         |
| 3.3% in Tanzania                                |              | —         |
| 0.09% in Nigeria                                |              | —         |
| 0.05% in Mali                                   |              | —         |
| 0.3% in Angola                                  |              | —         |
| 0.44% in Sri Lanka                              |              | —         |
| 0.23% in Taiwan                                 |              | —         |
| 0.123% in China                                 |              | —         |

| GENES  | STUDY POPULATION | REFERENCE |
|--|------------------|-----------|
| HLA-C, IL23A, IL23R, IL23B, TNIP1, TNAIP3, IL4, IL13 |                  | —         |
| LCE3C, LCE3B   |                  | —         |
| NOS2, FBXL19, NFKBIA                                 | — —              | —         |
| Same set as Nair et al                               |                  | —         |
| IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFK-BIA, TYK2   |                  | —         |







—

—

—

—

— —

—

| DRUG        | TRIAL | STUDY PARTICIPANTS | DEMOGRAPHICS |
|-------------|-------|--------------------|--------------|
| Adalimumab  |       |                    |              |
| Etanercept  |       |                    |              |
| Ustekinumab |       |                    |              |

**Disclosure:**Dr. Alexis is a consultant for Amgen. Mr. Blackcloud reports no relevant conflicts of interest.

*J Invest Dermatol.*

*Dermatol Clin.*

*J Am Acad Dermatol.*

*J Am Acad Dermatol.*

*J Am Acad Dermatol.*

*Vital and health statistics Series 10, Data from the National Health Survey.*

*J Am Acad Dermatol.*

*Int J Dermatol.*

*J Am Acad Dermatol.*

*Am J Hum Genet.*

*J Autoimmun.*

*J*

*Nat Genet.*

*Br J Dermatol.*

J Am Acad Dermatol.

*N Engl J Med.*

*Br J Dermatol.*

*N Engl J Med.*

Matrix Medical Communications

